Thursday, July 03, 2025 5:52:06 PM
So you are saying that Dr. Roger Stupp has no opinion and no influence? There is such a thing as professional rivalry in addition to any financial interest. If anything, professional 'bragging rights' can run deeper than mere financial concern among famous inventors! BTW, please note that in the seminal Optune article, other doc authors reported owning NVCR stock, but Stupp only reported getting paid travel expenses. I'm NOT claiming he has any financial interest.
For that matter, I don't know that the researchers who came out of the woodwork to go on record bashing the dcVax trial had anything other than professional rivalry at stake. I've heard LL say that she doesn't accept the efficacy of TTF. All the more reason for her strong advocacy for the dc-vax approach. Do you think Stupp doesn't advocate just as strongly FOR TTF? And do you think anybody in the field has NOT heard of the 'Stupp protocol?' For those who might not know, here is Stupp's BIO:
Dr. Roger Stupp is an internationally renowned
medical oncologist and neuro-oncologist and
a leading authority on primary and metastatic
brain cancer. Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase registration studies.
In the brain tumor field, he is best known for his
contributions of temozolomide and radiation in
the first line treatment of brain tumors, MGMT
as a predictive factor for benefit from alkylating
agent chemotherapy (in collaboration with Monika Hegi) and establishing Tumor Treating Fields
as an innovative treatment modality.
Roger Stupp has been an active investigator
with the EORTC for over 25 years. He was a
member of the head and neck and brain tumor
groups and served for many years as the secretary to the BTG. Since 2006 Dr. Stupp serves on
the EORC board of directors, from 2012 – 2017
as the president. He developed concepts for
several innovative trials and acted as the principal
investigator for numerous phase 2 and phase 3
clinical trials that were conducted as international
trials under the umbrella of the EORTC.
For that matter, I don't know that the researchers who came out of the woodwork to go on record bashing the dcVax trial had anything other than professional rivalry at stake. I've heard LL say that she doesn't accept the efficacy of TTF. All the more reason for her strong advocacy for the dc-vax approach. Do you think Stupp doesn't advocate just as strongly FOR TTF? And do you think anybody in the field has NOT heard of the 'Stupp protocol?' For those who might not know, here is Stupp's BIO:
Dr. Roger Stupp is an internationally renowned
medical oncologist and neuro-oncologist and
a leading authority on primary and metastatic
brain cancer. Dr. Stupp has been the lead investigator for numerous clinical trials from first-in-human phase 1 to pivotal phase registration studies.
In the brain tumor field, he is best known for his
contributions of temozolomide and radiation in
the first line treatment of brain tumors, MGMT
as a predictive factor for benefit from alkylating
agent chemotherapy (in collaboration with Monika Hegi) and establishing Tumor Treating Fields
as an innovative treatment modality.
Roger Stupp has been an active investigator
with the EORTC for over 25 years. He was a
member of the head and neck and brain tumor
groups and served for many years as the secretary to the BTG. Since 2006 Dr. Stupp serves on
the EORC board of directors, from 2012 – 2017
as the president. He developed concepts for
several innovative trials and acted as the principal
investigator for numerous phase 2 and phase 3
clinical trials that were conducted as international
trials under the umbrella of the EORTC.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
